CMPS on Nasdaq

Compass Pathways

Logo: compasspathways.com4

British psychedelic medicine company

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 18, 2026.

Overview

Jun 13, 2016Founded1

Compare with another stock.

  • TickerCMPS on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersLondon1
  • Websitecompasspathways.com
  • Legal formpublic limited company1
  • Incorporated inUnited Kingdom5
  • Business address3Rd Floor, 1 Ashley Road, Altrincham, Chesire, X0 Wa14 2Dt5
  • Filer categoryNon-accelerated filer, Smaller reporting company5

See how the biggest companies compare on our leaderboards

Compass Pathways image from its website
Image: compasspathways.com4

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income678910-$179.0M in 2025+745% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$21.2M-$21.2M20192020: -$51.4M-$51.4M2020+143%2021: -$83.2M-$83.2M2021+62%2022: -$110.4M-$110.4M2022+33%2023: -$136.9M-$136.9M2023+24%2024: -$178.2M-$178.2M2024+30%2025: -$179.0M-$179.0M2025+0%
Net income678910-$287.9M in 2025+1368% since 2019
-$300.0M-$200.0M-$100.0M02019: -$19.6M-$19.6M20192020: -$60.3M-$60.3M2020+208%2021: -$71.7M-$71.7M2021+19%2022: -$91.5M-$91.5M2022+28%2023: -$118.5M-$118.5M2023+29%2024: -$155.1M-$155.1M2024+31%2025: -$287.9M-$287.9M2025+86%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$118.4M$119.0M
General and administrative$60.6M$59.2M
Total operating expenses$179.0M$178.2M
LOSS FROM OPERATIONS:-$179.0M-$178.2M
Fair value change of warrant liabilities-$122.6M$0
Benefit from R&D tax credit$3.7M$21.1M
Interest income$7.2M$8.3M
Interest expense-$4.5M-$4.5M
Foreign exchange gains (losses)$3.5M-$1.0M
Other income$1.4M$823.0K
Total other (expense) income, net-$111.3M$24.7M
Loss before income taxes-$290.3M-$153.5M
Income tax benefit (expense)$2.5M-$1.6M
Net loss-$287.9M-$155.1M
Net loss per share attributable to ordinary shareholders - basic (in dollars per share)-$3.08-$2.30
Net loss per share attributable to ordinary shareholders - diluted (in dollars per share)-$3.08-$2.30
Weighted average ordinary shares outstanding - basic (in shares)93.5M shares67.5M shares
Weighted average ordinary shares outstanding - diluted (in shares)93.5M shares67.5M shares
Foreign exchange translation adjustment$1.4M$732.0K
Comprehensive loss-$286.5M-$154.4M

Compare Compass Pathways with another company

Leadership

Who has led Compass Pathways, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. George Jay Goldsmith2022
  2. Kabir Nath2022–now

Chief financial officer

  1. Michael Falvey2022–2023
  2. Teri Loxam2024–now
20202025
Board members and other officers (18)

Former names

  • Compass Rx Ltd.Jul 2, 2020 to Aug 10, 20205

Timeline

  1. Aug 3, 2022New chief executive Kabir Nath becomes CEO15
  2. Jan 3, 2022New chief executive George Jay Goldsmith becomes CEO14
  3. Sep 2020Went public Listed on NASDAQ1
  4. Jun 13, 2016Founded Founded1

Filings

294 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 48 major events, 137 insider forms, 32 large holders, 58 other. The latest 20:

  1. Aug 10, 2026144 EDGAR
  2. Aug 7, 2026144 EDGAR
  3. Aug 5, 20264 EDGAR
  4. Aug 5, 2026S-3ASR EDGAR
  5. Aug 5, 20268-K EDGAR
  6. Aug 5, 202610-Q EDGAR
  7. Jul 7, 20268-K EDGAR
  8. May 29, 20264 EDGAR
  9. May 29, 20264 EDGAR
  10. May 29, 20263 EDGAR
  11. May 29, 20264 EDGAR
  12. May 29, 20264 EDGAR
  13. May 29, 20264 EDGAR
  14. May 29, 20264 EDGAR
  15. May 29, 20264 EDGAR
  16. May 29, 20264 EDGAR
  17. May 28, 20268-K EDGAR
  18. May 15, 2026SCHEDULE 13G/A EDGAR
  19. May 13, 20268-K EDGAR
  20. May 13, 202610-Q EDGAR

The 294 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 32 such filings since October 2021, the latest 10:

  1. May 15, 2026SCHEDULE 13G/A
  2. Feb 17, 2026SCHEDULE 13D/A
  3. Nov 14, 2025SCHEDULE 13G/A
  4. Nov 14, 2025SCHEDULE 13G/A
  5. Oct 29, 2025SCHEDULE 13D/A
  6. Aug 14, 2025SCHEDULE 13G/A
  7. Aug 14, 2025SCHEDULE 13G
  8. Aug 14, 2025SCHEDULE 13G/A
  9. May 15, 2025SCHEDULE 13G/A
  10. May 15, 2025SCHEDULE 13G

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Deep Track Capital, LP12,161,496$172.1M2.5%No change
Rtw Investments, LP10,700,974$151.4M1.3%+68,584
BIT Capital GmbH6,348,797$89.8M3.1%+2,857,563
Tang Capital Management LLC5,000,000$70.8M3.2%+997,800
Two Sigma Investments, LP4,470,485$63.3M0.0%+1,886,986
Marshall Wace, Llp4,328,682$61.3M0.1%+290,347
ARK Investment Management LLC3,451,965$48.8M0.3%+150,915
Point72 Asset Management, L.P.2,620,878$37.1M0.1%New
Logos Global Management LP2,250,000$31.8M1.4%New
Eagle Health Investments LP2,060,427$29.2M4.8%No change
Bank Of America Corp /de/2,019,348$28.6M0.0%+1,987,016
DAFNA Capital Management LLC2,011,952$28.5M5.4%−406,930
NEXTBio Capital Management LP1,775,759$25.1M11.6%−245,648
Kalehua Capital Management LLC1,639,384$23.2M7.4%No change
UBS Group AG1,482,470$21.0M0.0%−372,600
Aisling Capital Management LP1,432,336$20.3M4.3%No change
Renaissance Technologies LLC1,431,889$20.3M0.0%+566,535
Candriam S.C.A.1,274,278$18.0M0.1%New
Woodline Partners LP1,086,004$15.4M0.0%+910,565
Citadel Advisors LLC1,004,880$14.2M0.0%+735,391
Jefferies Financial Group Inc.994,393$14.1M0.1%−472,969
BlackRock, Inc.925,391$13.1M0.0%+242,150
Trexquant Investment LP860,158$12.2M0.1%+550,875
Millennium Management LLC770,987$10.9M0.0%−2,367,535
Caption Management, LLC756,116$10.7M0.4%−854,014

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jan 23, 2023Shri ThanedarDemocratic, HouseSale$1,001 - $15,000+89.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteCompass Pathways logo
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33